CEP290 and retinitis pigmentosa: However, more studies are considering the use of CRISPR/Cas9 systems, such as Editas Medicine, which is targeting LCA10 caused by CEP290 mutations, or modifier therapy, such as Ocugen, Inc., which has a product (OCU400) in clinical trials for retinitis pigmentosa associated with mutations in NR2E3, RHO, and CEP290 genes.